|
1
|
Gosch M, Kammerlander C and Nicholas JA:
Treatment of osteoporosis in older adults. Panminerva Med.
56:133–143. 2014.PubMed/NCBI
|
|
2
|
Kurra S, Fink DA and Siris ES:
Osteoporosis-associated fracture and diabetes. Endocrinol Metab
Clin North Am. 43:233–243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maeda SS and Lazaretti-Castro M: An
overview on the treatment of postmenopausal osteoporosis. Arq Bras
Endocrinol Metabol. 58:162–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yun H, Delzell E, Saag KG, Kilgore ML,
Morrisey MA, Muntner P, Matthews R, Guo L, Wright N, Smith W, et
al: Fractures and mortality in relation to different osteoporosis
treatments. Clin Exp Rheumatol. 33:302–309. 2015.
|
|
5
|
Hegyi L: The risk of immobility in
geriatrics. Eurorehab. 3:151–154. 2001.
|
|
6
|
Rachner TD, Khosla S and Hofbauer LC:
Osteoporosis: Now and the future. Lancet. 377:1276–1287. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Malluche HH, Koszewski N, Monier-Faugere
MC, Williams JP and Mawad H: Influence of the parathyroid glands on
bone metabolism. Eur J Clin Invest. 36(Suppl 2): S23–S33. 2006.
View Article : Google Scholar
|
|
8
|
Li B, Wang Y, Liu Y, Ma J and Li Y:
Altered gene expression involved in insulin signaling pathway in
type II diabetic osteoporosis rat model. Endocrine. 43:136–146.
2013. View Article : Google Scholar
|
|
9
|
Kameda Y, Takahata M, Mikuni S, Shimizu T,
Hamano H, Angata T, Hatakeyama S, Kinjo M and Iwasaki N: Siglec-15
is a potential therapeutic target for postmenopausal osteoporosis.
Bone. 71:217–226. 2015. View Article : Google Scholar
|
|
10
|
Canalis E: Wnt signalling in osteoporosis:
Mechanisms and novel therapeutic approaches. Nat Rev Endocrinol.
9:575–583. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Manolagas SC: Wnt signaling and
osteoporosis. Maturitas. 78:233–237. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu J, Mao Z, He S, Zhan Y, Ning R, Liu W,
Yan B and Yang J: Icariin protects against glucocorticoid induced
osteoporosis, increases the expression of the bone enhancer DEC1
and modulates the PI3K/Akt/GSK3β/β-catenin integrated signaling
pathway. Biochem Pharmacol. 136:109–121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Y, Wang X, Chang H, Gao X, Dong C, Li
Z, Hao J, Wang J and Fan Q: Mongolian Medicine echinops prevented
postmenopausal osteoporosis and induced ER/AKT/ERK pathway in
BMSCs. Biosci Trends. 12:275–281. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cong Q, Jia H, Li P, Qiu S, Yeh J, Wang Y,
Zhang ZL, Ao J, Li B and Liu H: p38alpha MAPK regulates
proliferation and differentiation of osteoclast progenitors and
bone remodeling in an aging-dependent manner. Sci Rep. 7:459642017.
View Article : Google Scholar
|
|
15
|
Pan BL, Tong ZW, Li SD, Wu L, Liao JL,
Yang YX, Li HH, Dai YJ, Li JE and Pan L: Decreased microRNA-182-5p
helps alendronate promote osteoblast proliferation and
differentiation in osteoporosis via the Rap1/MAPK pathway. Biosci
Rep. 38:BSR201806962018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong W, Qi M, Wang Y, Feng X and Liu H:
Zoledronate and high glucose levels influence osteoclast
differentiation and bone absorption via the AMPK pathway. Biochem
Biophys Res Commun. 505:1195–1202. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
de Pablos RM, Espinosa-Oliva AM,
Hornedo-Ortega R, Cano M and Arguelles S: Hydroxytyrosol protects
from aging process via AMPK and autophagy, a review of its effects
on cancer, metabolic syndrome, osteoporosis, immune-mediated and
neurodegenerative diseases. Pharmacol Res. 143:58–72. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Buchwald ZS, Yang C, Nellore S, Shashkova
EV, Davis JL, Cline A, Ko J, Novack DV, DiPaolo R and Aurora R: A
bone anabolic effect of RANKL in a murine model of osteoporosis
mediated through FoxP3+ CD8 T cells. J Bone Miner Res.
30:1508–1522. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qi J, Hu KS and Yang HL: Roles of TNF-α,
GSK-3β and RANKL in the occurrence and development of diabetic
osteoporosis. Int J Clin Exp Pathol. 8:11995–2004. 2015.
|
|
20
|
Guo L, Tang K, Quan Z, Zhao Z and Jiang D:
Association between seven common OPG genetic polymorphisms and
osteoporosis risk: A meta-analysis. DNA Cell Biol. 33:29–39. 2014.
View Article : Google Scholar
|
|
21
|
Lin H, Zhang G, Chen X, Wu X, Wu C, Ca H
and Hu Z: The relationship between the g.27450A>T genetic
variant of OPG gene and osteoporosis in Chinese postmenopausal
women. Int Immunopharmacol. 21:464–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brunetti G, Storlino G, Oranger A,
Colaianni G, Faienza MF, Ingravallo G, Di Comite M, Reseland JE,
Celi M, Tarantino U, et al: LIGHT/TNFSF14 regulates estrogen
deficiency-induced bone loss. J Pathol. 250:440–451. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X, Liang T, Zhu Y, Qiu J, Qiu X, Lian
C, Gao B, Peng Y, Liang A, Zhou H, et al: Melatonin prevents bone
destruction in mice with retinoic acid-induced osteoporosis. Mol
Med. 25:432019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Negishi-Koga T and Takayanagi H:
Ca2+-NFATc1 signaling is an essential axis of osteoclast
differentiation. Immunol Rev. 231:241–256. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
An J, Hao D, Zhang Q, Chen B, Zhang R,
Wang Y and Yang H: Natural products for treatment of bone erosive
diseases: The effects and mechanisms on inhibiting
osteoclastogenesis and bone resorption. Int Immunopharmacol.
36:118–131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ledesma-Colunga MG, Adán N, Ortiz G,
Solís-Gutiérrez M, López-Barrera F, Martínez de la Escalera G and
Clapp C: Prolactin blocks the expression of receptor activator of
nuclear factor κB ligand and reduces osteoclastogenesis and bone
loss in murine inflammatory arthritis. Arthritis Res Ther.
19:932017. View Article : Google Scholar
|
|
27
|
Chai L, Zhou K, Wang S, Zhang H, Fan N, Li
J, Tan X, Hu L and Fan X: Psoralen and bakuchiol ameliorate M-CSF
plus RANKL-induced osteoclast differentiation and bone resorption
via inhibition of AKT and AP-1 pathways in vitro. Cell Physiol
Biochem. 48:2123–2133. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu W and Zhang X: Receptor activator of
nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in
bone and other tissues (review). Mol Med Rep. 11:3212–3218. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park JH, Lee NK and Lee SY: Current
understanding of RANK signaling in osteoclast differentiation and
maturation. Mol Cells. 40:706–713. 2017.PubMed/NCBI
|
|
30
|
Naidu VG, Dinesh Babu KR, Thwin MM, Satish
RL, Kumar V and Gopalakrishnakone P: RANKL targeted peptides
inhibit osteoclastogenesis and attenuate adjuvant induced arthritis
by inhibiting NF-κB activation and down regulating inflammatory
cytokines. Chem Biol Interact. 203:467–479. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qin S, Zhang Q and Zhang L: Effect of OPG
gene mutation on protein expression and biological activity in
osteoporosis. Exp Ther Med. 14:1475–1480. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dai XM, Ryan GR, Hapel AJ, Dominguez MG,
Russell RG, Kapp S, Sylvestre V and Stanley ER: Targeted disruption
of the mouse CSF-1 receptor gene results in osteopetrosis,
mono-nuclear phagocyte deficiency, increased primitive progenitor
cell frequencies and reproductive defects. Blood. 99:111–120. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng C, Wentworth K and Shoback DM: New
frontiers in osteoporosis therapy. Annu Rev Med. 71:277–288. 2020.
View Article : Google Scholar
|
|
34
|
Claustrat B and Leston J: Melatonin:
Physiological effects in humans. Neurochirurgie. 61:77–84. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tan DX and Reiter RJ: Mitochondria: The
birth place, battle ground and the site of melatonin metabolism in
cells. Melat Res. 2:44–66. 2019. View Article : Google Scholar
|
|
36
|
Claustrat B, Geoffriau M, Brun J and
Chazot G: Melatonin in humans: A biochemical marker of the
circadian clock and an endogenous synchronizer. Neurophysiol Clin.
25:351–359. 1995.In French. View Article : Google Scholar
|
|
37
|
Vural EM, van Munster BC and de Rooij SE:
Optimal dosages for melatonin supplementation therapy in older
adults: A systematic review of current literature. Drugs Aging.
31:441–451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
van Faassen M, Bischoff R and Kema IP:
Relationship between plasma and salivary melatonin and cortisol
investigated by LC-MS/MS. Clin Chem Lab Med. 55:1340–1348. 2017.
View Article : Google Scholar
|
|
39
|
Claustrat B, Brun J and Chazot G: The
basic physiology and pathophysiology of melatonin. Sleep Med Rev.
9:11–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Amaral FGD and Cipolla-Neto J: A brief
review about melatonin, a pineal hormone. Arch Endocrinol Metab.
62:472–479. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sánchez-Barceló EJ, Mediavilla MD, Tan DX
and Reiter RJ: Scientific basis for the potential use of melatonin
in bone diseases: Osteoporosis and adolescent idiopathic scoliosis.
J Osteoporos. 2010:8302312010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
43
|
Jacome-Galarza CE, Percin GI, Muller JT,
Mass E, Lazarov T, Eitler J, Rauner M, Yadav VK, Crozet L, Bohm M,
et al: Developmental origin, functional maintenance and genetic
rescue of osteoclasts. Nature. 568:541–545. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhou L, Chen X, Yan J, Li M, Liu T, Zhu C,
Pan G, Guo Q, Yang H, Pei M and He F: Melatonin at pharmacological
concentrations suppresses osteoclastogenesis via the attenuation of
intracellular ROS. Osteoporos Int. 28:3325–3337. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim HJ, Kim HJ, Bae MK and Kim YD:
Suppression of osteoclastogenesis by melatonin: A melatonin
receptor-independent action. Int J Mol Sci. 18:11422017. View Article : Google Scholar :
|
|
46
|
Sifat M, Samsonraj RM, Munmun F, Glas J,
Silvestros M, Kotlarczyk MP, Rylands R, Dudakovic A, van Wijnen AJ,
Enderby LT, et al: Biological effects of melatonin on
osteoblast/osteoclast cocultures, bone, and quality of life:
Implications of a role for MT2 melatonin receptors, MEK1/2, and
MEK5 in melatonin-mediated osteoblastogenesis. J Pineal Res.
64:2018.
|
|
47
|
Ping Z, Wang Z, Shi J, Wang L, Guo X, Zhou
W, Hu X, Wu X, Liu Y, Zhang W, et al: Inhibitory effects of
melatonin on titanium particle-induced inflammatory bone resorption
and osteoclastogenesis via suppression of NF-κB signaling. Acta
Biomater. 62:362–371. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Song C, Tan P, Zhang Z, Wu W, Dong Y, Zhao
L, Liu H, Guan H and Li F: REV-ERB agonism suppresses
osteoclastogenesis and prevents ovariectomy-induced bone loss
partially via FABP4 upregulation. FASEB J. 32:3215–3228. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhou X, Yu R, Long Y, Zhao J, Yu S, Tang Q
and Chen L: BMAL1 deficiency promotes skeletal mandibular
hypoplasia via OPG downregulation. Cell Prolif. 51:e124702018.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tang Z, Xu T, Li Y, Fei W, Yang G and Hong
Y: Inhibition of CRY2 by STAT3/miRNA-7-5p promotes osteoblast
differentiation through upregulation of CLOCK/BMAL1/P300
expression. Mol Ther Nucleic Acids. 19:865–876. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Song C, Wang J, Kim B, Lu C, Zhang Z, Liu
H, Kang H, Sun Y, Guan H, Fang Z and Li F: Insights into the role
of circadian rhythms in bone metabolism: A promising intervention
target? BioMed Res Int. 2018:91564782018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kunimoto T, Okubo N, Minami Y, Fujiwara H,
Hosokawa T, Asada M, Oda R, Kubo T and Yagita K: A PTH-responsive
circadian clock operates in ex vivo mouse femur fracture healing
site. Sci Rep. 6:224092016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gibbs JE, Blaikley J, Beesley S, Matthews
L, Simpson KD, Boyce SH, Farrow SN, Else KJ, Singh D, Ray DW and
Loudon AS: The nuclear receptor REV-ERBα mediates circadian
regulation of innate immunity through selective regulation of
inflammatory cytokines. Proc Natl Acad Sci USA. 109:582–587. 2012.
View Article : Google Scholar
|
|
54
|
Vieira E, Merino B and Quesada I: Role of
the clock gene Rev-erbalpha in metabolism and in the endocrine
pancreas. Diabetes Obes Metab. 17(Suppl 1): S106–S114. 2015.
View Article : Google Scholar
|
|
55
|
Lam MT, Cho H, Lesch HP, Gosselin D, Heinz
S, Tanaka-Oishi Y, Benner C, Kaikkonen MU, Kim AS, Kosaka M, et al:
Rev-Erbs repress macrophage gene expression by inhibiting
enhancer-directed transcription. Nature. 498:511–515. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sato S, Sakurai T, Ogasawara J, Takahashi
M, Izawa T, Imaizumi K, Taniguchi N, Ohno H and Kizaki T: A
circadian clock gene, Rev-erbα, modulates the inflammatory function
of macrophages through the negative regulation of Ccl2 expression.
J Immunol. 192:407–417. 2014. View Article : Google Scholar
|
|
57
|
Mazzoccoli G, Cai Y, Liu S, Francavilla M,
Giuliani F, Piepoli A, Pazienza V, Vinciguerra M, Tamamoto T and
Takumi T: REV-ERBalpha and the clock gene machinery in mouse
peripheral tissues: A possible role as a synchronizing hinge. J
Biol Regul Homeost Agents. 26:265–276. 2012.PubMed/NCBI
|
|
58
|
Wang S, Gu X, Zhang Q, Zhang X, Li Y, Yao
Y, Yu B and Zhang Y: Angiotensin II suppresses Rev-erbα expression
in THP-1 macrophages via the Ang II type 1 receptor/liver X
receptor α pathway. Cell Physiol Biochem. 46:303–313. 2018.
View Article : Google Scholar
|
|
59
|
Roby DA, Ruiz F, Kermath BA, Voorhees JR,
Niehoff M, Zhang J, Morley JE, Musiek ES, Farr SA and Burris TP:
Pharmacological activation of the nuclear receptor REV-ERB reverses
cognitive deficits and reduces amyloid-β burden in a mouse model of
Alzheimer's disease. PloS One. 14:e02150042019. View Article : Google Scholar
|
|
60
|
Welch RD and Flaveny CA: REV-ERB and ROR:
Therapeutic targets for treating myopathies. Phys Biol.
14:0450022017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Solt LA, Wang Y, Banerjee S, Hughes T,
Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, et al:
Regulation of circadian behavior and metabolism by synthetic
REV-ERB agonists. Nature. 485:62–68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Thevis M and Schänzer W: Emerging drugs
affecting skeletal muscle function and mitochondrial biogenesis -
Potential implications for sports drug testing programs. Rapid
Commun Mass Spectrom. 30:635–651. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Mazzarino M, Rizzato N, Stacchini C, de la
Torre X and Botrè F: A further insight into the metabolic profile
of the nuclear receptor Rev-erb agonist, SR9009. Drug Test Anal.
10:1670–1681. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kojetin D, Wang Y, Kamenecka TM and Burris
TP: Identification of SR8278, a synthetic antagonist of the nuclear
heme receptor REV-ERB. ACS Chem Biol. 6:131–134. 2011. View Article : Google Scholar :
|
|
65
|
Lee J, Kim DE, Griffin P, Sheehan PW, Kim
DH, Musiek ES and Yoon SY: Inhibition of REV-ERBs stimulates
microglial amyloid-beta clearance and reduces amyloid plaque
deposition in the 5XFAD mouse model of Alzheimer's disease. Aging
Cell. 19:e130782020. View Article : Google Scholar
|
|
66
|
Kim K, Kim JH, Kim I, Seong S and Kim N:
Rev-erbα Negatively Regulates Osteoclast and Osteoblast
Differentiation through p38 MAPK Signaling Pathway. Mol Cells.
43:34–47. 2020.PubMed/NCBI
|
|
67
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bolland MJ, Grey A and Reid IR: Should we
prescribe calcium or vitamin D supplements to treat or prevent
osteoporosis. Climacteric. 18(Suppl 2): S22–S31. 2015. View Article : Google Scholar
|
